Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Isolated polycystic liver disease genes define effectors of polycystin-1 function
Whitney Besse, Ke Dong, Jungmin Choi, Sohan Punia, Sorin V. Fedeles, Murim Choi, Anna-Rachel Gallagher, Emily B. Huang, Ashima Gulati, James Knight, Shrikant Mane, Esa Tahvanainen, Pia Tahvanainen, Simone Sanna-Cherchi, Richard P. Lifton, Terry Watnick, York P. Pei, Vicente E. Torres, Stefan Somlo
Whitney Besse, Ke Dong, Jungmin Choi, Sohan Punia, Sorin V. Fedeles, Murim Choi, Anna-Rachel Gallagher, Emily B. Huang, Ashima Gulati, James Knight, Shrikant Mane, Esa Tahvanainen, Pia Tahvanainen, Simone Sanna-Cherchi, Richard P. Lifton, Terry Watnick, York P. Pei, Vicente E. Torres, Stefan Somlo
View: Text | PDF | Corrigendum
Research Article Genetics Nephrology

Isolated polycystic liver disease genes define effectors of polycystin-1 function

  • Text
  • PDF
Abstract

Dominantly inherited isolated polycystic liver disease (PCLD) consists of liver cysts that are radiologically and pathologically identical to those seen in autosomal dominant polycystic kidney disease, but without clinically relevant kidney cysts. The causative genes are known for fewer than 40% of PCLD index cases. Here, we have used whole exome sequencing in a discovery cohort of 102 unrelated patients who were excluded for mutations in the 2 most common PCLD genes, PRKCSH and SEC63, to identify heterozygous loss-of-function mutations in 3 additional genes, ALG8, GANAB, and SEC61B. Similarly to PRKCSH and SEC63, these genes encode proteins that are integral to the protein biogenesis pathway in the endoplasmic reticulum. We inactivated these candidate genes in cell line models to show that loss of function of each results in defective maturation and trafficking of polycystin-1, the central determinant of cyst pathogenesis. Despite acting in a common pathway, each PCLD gene product demonstrated distinct effects on polycystin-1 biogenesis. We also found enrichment on a genome-wide basis of heterozygous mutations in the autosomal recessive polycystic kidney disease gene PKHD1, indicating that adult PKHD1 carriers can present with clinical PCLD. These findings define genetic and biochemical modulators of polycystin-1 function and provide a more complete definition of the spectrum of dominant human polycystic diseases.

Authors

Whitney Besse, Ke Dong, Jungmin Choi, Sohan Punia, Sorin V. Fedeles, Murim Choi, Anna-Rachel Gallagher, Emily B. Huang, Ashima Gulati, James Knight, Shrikant Mane, Esa Tahvanainen, Pia Tahvanainen, Simone Sanna-Cherchi, Richard P. Lifton, Terry Watnick, York P. Pei, Vicente E. Torres, Stefan Somlo

×

Figure 2

Mutations in ALG8 cause abnormal biogenesis of PC1.

Options: View larger image (or click on image) Download as PowerPoint
Mutations in ALG8 cause abnormal biogenesis of PC1.
(A) YU313 has innume...
(A) YU313 has innumerable liver cysts larger than 1 cm (circle). (B) T-70 has innumerable small liver cysts (arrows). (C) W-YU363 has innumerable liver cysts, many larger than 1 cm (arrows, top panel), and 3–4 kidney cysts (arrows, bottom panel), while his 19-year-old daughter, YU364 (D), has the same ALG8 mutation but 8 kidney cysts (arrows, top and bottom panels) and no liver cysts. (E and F) Immunoblots of cell lysates with anti-HA (E) and anti-LRR PC1 N-terminal antibody (7e12) (F) show decreased PC1-CTF, PC1-FL, PC1-NTR, and PC1-NTS in Alg8–/– cells. Re-expression of Alg8+ in Alg8–/– cells rescues PC1 expression (F). The labels in red mark the migration of the respective PC1 fragments in the Alg8–/– cell lysate. (G and H) Anti-HA immunoprecipitation of PC1-FL and PC1-CTF was treated with PNGase F or EndoH. (G) Altered migration of PC1-FL is due to hypoglycosylation in Alg8–/– cells. PNGase F treatment shows equivalent deglycosylated PC1-FL migration. (H) The relative proportion of EndoH-resistant/EndoH-sensitive PC1-CTF is reduced in Alg8–/– cells. In G and H, the 2 PC1-CTF bands in the PNGase F–treated lanes result from alternatively spliced forms present in rodents (66). (I) Immunofluorescence shows absence of detectable PC1 (anti-HA) in cilia of Alg8–/– cells. (J) Alg8–/– cells activate the IRE1α/XBP1 branch of UPR, demonstrated by presence of XBP1s by reverse transcription PCR (RT-PCR; top) and immunoblotting (bottom). (K) Anti-HA immunoblot shows that inactivation of both Alg8 and Xbp1 does not change PC1 hypoglycosylation or GPS cleavage compared with Alg8 knockout alone. HSP90 serves as loading control for cell lysates.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts